During pregnancy, the maternal immune response changes dramatically over the course of gestation. This has implications for generation of lactogenic immunity and subsequent protection in suckling neonates against enteric viral infections. For example, porcine epidemic diarrhea virus (PEDV) is an alphacoronavirus that causes acute diarrhea in neonatal piglets. Due to the high virulence of PEDV and the naïve, immature immune system of neonatal suckling piglets, passive lactogenic immunity to PEDV induced during pregnancy, via the gut-mammary gland (MG)-secretory IgA (sIgA) axis, is critical for piglet protection. However, the anti-PEDV immune response during pregnancy and stage of gestation required to optimally stimulate the gut-MG-sIgA axis is undefined. We hypothesize that there is a gestational window in which non-lethal PEDV infection of pregnant gilts influences maximum lymphocyte mucosal trafficking to the MG, resulting in optimal passive lactogenic protection in suckling piglets. To understand how the stages of gestation affect maternal immune responses to PEDV, three groups of gilts were orally infected with PEDV in the first, second or third trimester. Control (mock) gilts were inoculated with medium in the third trimester. To determine if lactogenic immunity correlated with protection, all piglets were PEDV-challenged at 3-5 days postpartum. PEDV infection of gilts at different stages of gestation significantly affected multiple maternal systemic immune parameters prepartum, including cytokines, B cells, PEDV antibodies (Abs), and PEDV antibody secreting cells (ASCs). Pregnant second trimester gilts had significantly higher levels of circulating PEDV IgA and IgG Abs and ASCs and PEDV virus neutralizing (VN) Abs post PEDV infection. Coinciding with the significantly higher PEDV Ab responses in second trimester gilts, the survival rate of their PEDV-challenged piglets was 100%, compared with 87.2, 55.9, and 5.7% for first, third, and mock litters, respectively. Additionally, piglet survival positively correlated with PEDV Langel et al.
INTRODUCTION
Diarrheal diseases in young animals account for an estimated multi-million dollar loss to the livestock industry annually due to the livestock industry annually due to mortality, reduced weight gain, treatment costs, and trade sanctions on exporting animal products from infected countries (1, 2) . For example, porcine epidemic diarrhea virus (PEDV) is a highly virulent re-emerging enteric coronavirus that causes acute diarrhea, dehydration, and death in neonatal piglets (3) . It has killed over 8.5 million piglets since its emergence in the US in 2013. In adult pigs, PEDV causes watery diarrhea, depression, and anorexia as well as agalactia and reduced reproductive performance (1) (2) (3) . Lactogenic immunity remains the most promising and effective way to protect neonatal suckling piglets from enteric diseases like PEDV (4, 5) . This is dependent on trafficking of pathogen-specific IgA + plasmablasts to the mammary gland (MG) and accumulation of secretory IgA (sIgA) antibodies (Abs) in milk, defined as the gut-MG-sIgA axis (6) (7) (8) . Understanding the regulation of mucosal homing receptor and chemokine expression is critical to generate sufficient lactogenic immunity for piglet protection. For example, chemokine receptor (CCR)10, a lymphocyte gut homing marker, is required for IgA + plasmablast recruitment to the MG in mice and humans (9) (10) (11) . Additionally, an increase in lymphocyte migration to the MG in swine at the end of gestation and during lactation coincides with an increase in α 4 β 7 integrin, another lymphocyte gut homing marker, on B cells (12) . Identifying factors that influence lymphocyte migration and the gut-MGsIgA axis may lead to improved PEDV vaccine regimens in gestating swine, boosting overall herd immunity and health and industry productivity.
Maternal vaccination that increases the amount of passively transferred protective Abs in milk, induced via the gut-MGsIgA axis, is the strategy used to protect suckling piglets from PEDV immediately after birth (4, 5) . For example, in swine, high rates of protection against another porcine enteric alphacoronavirus, transmissible gastroenteritis virus (TGEV) in piglets is achieved when pregnant sows are orally infected with live virulent virus (5) (6) (7) (13) (14) (15) . The increased rate of protection was associated with high titers of IgA Abs in colostrum and milk. This demonstrates that enteric viral infection stimulates the intestinal mucosa influencing lactogenic immunity via the gut-MG-sIgA axis (4, 5) . This model system can be used in the context of PEDV, as similar maternal vaccination strategies are needed for initiation of the gut-MG-sIgA axis and piglet protection (4, 12, 16, 17) . We showed previously in third trimester pregnant gilts that administering a higher dose of virulent PEDV increased virus neutralizing (VN) Ab titers in colostrum/milk and piglet protection compared with a lower dose (4) . Despite this, field reports demonstrate incomplete and variable protection in orally PEDV-infected gestating swine (4) . Furthermore, the optimal stage of gestation to initiate the gut-MG-sIgA axis by means of natural infection or oral vaccination in naïve pregnant swine to generate protective lactogenic immunity is unknown.
Pregnancy modulates immunological processes that change over the course of gestation (18) . For example, during the first trimester of gestation, levels of innate and proinflammatory factors increase, facilitating embryo implantation (19, 20) . As pregnancy progresses, inflammatory cytokines decrease and regulatory cells and cytokines increase to support fetal growth and development to prevent rejection of the fetus (21) (22) (23) (24) . In the third trimester of gestation, the immunoregulatory environment is retained until immediately prior to parturition when proinflammatory and tissue repair factors increase, promoting the contraction of the uterus and expulsion of the fetus and placenta (18) . The ability of pregnancy to differentially modulate the immune response explains why the severity of illness and efficacy of vaccination is dependent on stage of gestation. For example, the risk and severity of influenza (25) , malaria (26) , and listeria (27) is higher for women in their third trimester than other gestational stages. Additionally, in women vaccinated with the trivalent inactivated influenza vaccine, seroconversion rates were higher in late third trimester compared with first trimester-vaccinated women (28) . Due to the differences in immune responses at different stages of pregnancy, it is important to consider stage of gestation when designing vaccines aimed to increase lactogenic immunity and passive transfer of protective Abs in colostrum/milk from mother to neonate.
In this study, we infected pregnant first parity gilts in their first, second and third trimesters of gestation with PEDV to determine the impact of stage of gestation on generation of maternal B-cell immunity, the gut-MG-sIgA axis and lactogenic immune protection in PEDV challenged piglets. Our goal was to identify innate and adaptive immune factors during pregnancy that influence lymphocyte trafficking, in addition to immune correlates of lactogenic immune protection in neonatal suckling piglets. Understanding the impact of stage of gestation at PEDV infection or exposure on maternal immunity will allow more precise maternal vaccination protocols to target the time when the animal is most immunologically responsive. Optimizing vaccine efficacy for gestating and lactating animals will enhance lactogenic immunity in neonates and decrease morbidity and mortality associated with neonatal enteric disease.
RESULTS

Overall Summary of Results and Significance for the Major Immune and PEDV Protection Parameters Assessed
An overall summary of the statistically significant results (Table 1) illustrates that PEDV infection of gilts at different stages of gestation (Figure 1 ) affects multiple maternal systemic immune parameters prepartum, including natural killer (NK) cells, cytokines, B cells, and PEDV Abs and antibody secreting cells (ASCs). In addition, significant postpartum effects on lactogenic immune parameters in colostrum and milk were observed including significantly increased PEDV IgA (colostrum and milk) and IgG (colostrum only) ASCs and PEDV IgA Abs and VN Abs in PEDV-infected second trimester gilts ( Table 1) . Notably several gilt [PEDV IgA (colostrum and milk) and IgG (colostrum only) ASCs, Abs, and VN Abs] and piglet (serum PEDV IgA and IgG Abs) parameters were positively correlated with piglet survival rates ( Table 2) , demonstrating the association between IgA ASCs and Abs and VN Abs and lactogenic immune protection of suckling neonates. The detailed results for each parameter are described in the following sections.
Third Trimester Gilts Had Significantly Higher PEDV RNA Shedding Titers and More Severe PEDV-Induced Diarrhea Third trimester gilts had significantly higher PEDV RNA shedding titers at PID 2 compared with second trimester gilts (Figure 2A) . Additionally, second trimester gilts had delayed onset of PEDV RNA shedding compared with first and third trimester gilts. Fecal consistency scores at PID 4 were significantly higher in third compared with second and first trimester gilts and third trimester gilts were the only treatment group with clinical diarrhea (mean fecal consistency score of >1) ( Figure 2B ).
Stage of Gestation Modulated Innate Immune Parameters
Circulating NK cell frequencies were significantly higher in first trimester gilts at PID 0 compared with second or third trimester gilts ( Figure 3A) . At PID 6-8, peripheral NK cell activity was significantly higher in first compared with second and third trimester gilts ( Figure 3B ). Mean concentrations of serum IL-12, a cytokine essential for NK cell activation (29) and IL-22, a cytokine produced by subsets of T and NK cells (30) (31) (32) , were numerically higher at PID 0 in first compared with second and third trimester gilts (Figures 3C,D Figures 4A,B) . Additionally, numbers of circulating PEDV IgA ASCs were consistently higher than PEDV IgG ASCs in first, second and third trimester gilts at PID 6-8 and 12-17 ( Figures 4A,B) . PEDV IgA Ab titers were significantly higher in second trimester gilts at PID 6-8 compared with first trimester gilts ( Figure 4C ). Serum TGF-β, a cytokine important for IgA class-switching (37), was significantly higher at PID 0 and remained numerically higher at PID 6-8 and 12-17 in second compared with first and third trimester gilts ( Figure 4D) . Serum IL-6, a cytokine essential for Ab production (38) , was numerically higher at PID 0 and 6-8 in second trimester compared with first and third trimester gilts ( Figure 4E) . No significant differences were observed for serum PEDV IgG or VN Ab titers within the first 2 weeks post-PEDV infection but there was a trend for higher mean titers in second trimester gilts (Figures S4A,B) . >1 (fecal consistency was scored as follows: 0, normal; 1, pasty/semiliquid; 2, liquid; 3, watery). PEDV RNA shedding titers and fecal consistency scores were measured at PID 0, 2, 4, 6, 10, and 14. Different letters indicate significant differences among treatment groups at the same time point (mean ± SEM). Statistical analysis was performed using the two-way ANOVA with repeated measures and Bonferroni's correction for multiple comparisons. Asterisks indicate significant differences among treatment groups at the same time point (mean ± SEM). Statistical analysis was performed using the two-way ANOVA with repeated measures and Bonferroni's correction for multiple comparisons. *P < 0.05, **P < 0.01, ***P < 0.001.
Second Trimester Gilts Maintained Significantly Higher Levels of PEDV Specific ASCs and Abs Throughout Gestation
To Serum PEDV IgG Ab titers were significantly higher in second compared with first trimester gilts at GD 82-95 and 104-114 and third trimester gilts at GD 82-95 and 98-102 ( Figure 5D ). Similarly, PEDV VN Ab titers were significantly higher in second compared with first trimester gilts at all time points but only significantly higher than third trimester gilts at GD 82-95 and 98-102 ( Figure 5E ).
Stage of Gestation Modulated Phenotypes of Gut Homing Circulating B Lymphocytes Prepartum
Mean frequencies of circulating α4 + β7 + (gut homing phenotype) B lymphocytes in second and third trimester gilts were significantly higher compared with first trimester gilts at PID 0 and 6-8 ( Figure 6A ). Additionally, first trimester gilts had a delayed increase in α4 + β7 + B lymphocyte frequencies in blood post PEDV infection ( Figure 6A ). Frequencies of α4 + β7 + B lymphocytes were standardized among gilt treatment groups at uniform GDs in late pregnancy ( Figure 6B ). Third trimester gilts had numerically elevated frequencies of circulating α4 + β7 + B lymphocytes ( Figure 6B ) at GD 98-102 and 104-114 corresponding with PEDV RNA shedding in the feces at PID 6-8 and 12-17 ( Figure 2A) . The mean frequencies of circulating chemokine receptor type 10 (CCR10 + ) B lymphocytes were also measured post PEDV infection ( Figure 6C ) and standardized Gilts were sampled at gestation day (GD) 82-95, 98-102, and 104-114. Asterisks indicate significant differences among treatment groups at the same time point (mean ± SEM). Statistical analysis was performed using the two-way ANOVA with repeated measures and Bonferroni's correction for multiple comparisons. *P < 0.05, **P < 0.01, ***P < 0.001.
among gilt treatment groups at uniform GDs in late pregnancy ( Figure 6D ). No statistical differences among treatment groups were observed at PID 0, 6-8 or 12-17 ( Figure 6C ). However, third trimester gilts had significantly higher frequencies of circulating CCR10 + B lymphocytes at GD 98-102 (PID 6-8) compared with second and first trimester and mock gilts ( Figure 6D ). The increase in circulating CCR10 + B lymphocytes at GD 98-102 corresponded to peak PEDV RNA shedding titers at PID 6-8 ( Figure 2A ) in third trimester gilts. Additionally, significantly higher frequencies of activated B lymphocytes [CD2 − CD21 + (39)] were observed in the blood of second and third compared with first trimester gilts at PID 0, 6-8, and 12-17 ( Figure 6E ).
Second Trimester PEDV-Infected Gilts Provided Optimum Lactogenic Immune Protection Resulting in 100% Piglet Protection
To determine the effect of stage of gestation at time of PEDV infection on lactogenic immune protection, piglets were challenged with PEDV at 3-5 days of age. The number of viable piglets born were not statistically significant between treatment groups ( Figure S5 ). Second trimester PEDV infection of gilts resulted in 100% survival of PEDV challenged piglets ( Figure 7A ). First trimester gilts provided intermediate protection (87.2% survival) while third trimester gilts provided the least amount of protection (55.9% survival) among PEDVinfected gilts. Mock piglet's survival rate (5.7%) was significantly lower than all other treatment groups. Comparison of piglet weight gain revealed second trimester litters gained significantly more weight than all other treatment groups starting at post challenge day (PCD) 4 and lasting throughout the experiment ( Figure 7B ). First trimester litters had significantly higher normalized weights than third trimester litters at PCD 6, 7, and 9, but were similar thereafter. Mock litters were stunted (decreased or no weight gain) from PCD 1-7 and had the lowest normalized weights throughout the study. Lactogenic immune protection coincided with decreased PEDV RNA shedding titers where mean peak titers were 6.1 ± 0.2 log 10 copies/ml, 7.8 ± 0.3 log 10 copies/ml, 9.1 ± 0.3 log 10 copies/ml, and 10.1 ±.2 log 10 copies/ml for second, first, third, and mock litters, respectively ( Figure 7C ). Corresponding to increased weight gain and decreased PEDV RNA shedding titers, diarrhea scores were Asterisks indicate significant differences among treatment groups at the same time point (mean ± SEM). Statistical analysis was performed using the two-way ANOVA with repeated measures and Bonferroni's correction for multiple comparisons. *P < 0.05, **P < 0.01, ***P < 0.001.
significantly lower in second trimester litters throughout the study ( Figure 7D ). While first trimester litters had diarrhea, it was delayed and significantly lower than third trimester litters at PCD 2-5. Mock litters had diarrhea immediately at PCD 1, lasting through PCD 11 and diarrhea scores were significantly higher than all other treatment groups. Gilt mean PEDV RNA shedding titers and fecal consistency scores were measured post piglet challenge. Mock gilt PEDV RNA shedding titers were significantly higher at PCD 2-7 than first, second and third trimester PEDV-infected gilts and remained numerically higher until PCD 17 ( Figure S6A) . Additionally, first trimester gilt PEDV RNA shedding titers peaked at PCD 4, earlier compared with second and third trimester gilts ( Figure S6A ). Mock gilt fecal consistency scores were significantly higher at PCD 5-11 compared with first, second and third trimester PEDV-infected gilts ( Figure S6B) . Diarrhea was not observed in previously PEDV-infected gilts post piglet challenge ( Figure S6B ). 
Second Trimester Litters
Piglet Survival Rates Post PEDV Challenge Correlated With Increased PEDV IgA ASCs and Abs and VN Abs in Milk
In colostrum, PEDV IgA and IgG ASCs were significantly higher in second compared with first and third trimester gilts (Figures 9A,B) . However, in milk only PEDV IgA ASCs were significantly higher at postpartum day (PPD) 8-14/PCD 5-9 in second trimester gilts compared with all other treatment groups ( Figure 9A ). While PEDV IgA ASCs were maintained at high numbers in milk throughout lactation, milk PEDV IgG ASCs decreased significantly throughout the study (Figures 9A,B) . Similar to ASCs, PEDV IgA and IgG Abs were significantly higher in the colostrum of second compared with first (IgA and IgG) and Piglet diarrhea was determined by fecal consistency score >1 (fecal consistency was scored as follows: 0, normal; 1, pasty/semiliquid; 2, liquid; 3, watery). Piglet diarrhea scores and PEDV RNA shedding titers were measured at PCD 1-7, 9, 11, 13, 15, and 17. Different letters indicate significant differences among treatment groups at the same time point (mean ± SEM). Statistical analysis was performed using the two-way ANOVA with repeated measures and Bonferroni's correction for multiple comparisons.
third trimester (IgA) gilts (Figures 9C,D) . Additionally, PEDV VN Ab titers were significantly higher in colostrum in second compared with third trimester gilts ( Figure 9E ). After PEDV piglet challenge (PPD 8-14/PCD 5-9), PEDV IgA Ab titers in milk were significantly higher in second compared with third trimester gilts while PEDV IgG Ab titers were significantly higher in second compared with first trimester gilts (Figures 9C,D) . Lastly, PEDV VN Ab titers were significantly higher in milk at PPD 8-14/PCD 5-9 compared with first and third trimester gilts ( Figure 9E ). We observed a significant correlation between PEDV IgA and IgG ASCs, and IgA and VN Abs in colostrum and piglet survival ( Table 2) . However, in mid and late lactation milk, only PEDV IgA ASCs, and IgA and VN Abs were significantly correlated with piglet survival. No significant (P < 0.05) correlations were observed between milk IgG ASCs or Abs and piglet survival ( Table 2) . These correlations are consistent with our hypothesis that IgA ASC and Ab titers in milk are responsible for lactogenic immune protection in neonatal piglets against PEDV challenge.
PEDV Antibody + Cells Increased in the MG Post PEDV Challenge
Third trimester gilts had lower mean numbers of PEDV Ab + cells in the MG (2.7 ± 0.7) per microscopic field (30×) compared with second (6.1 ± 3.2) and first (6.9 ± 1.4) trimester gilts at GD 104-114 ( Figure S7 ). There were no PEDV Ab + cells in the MG of mock gilts prepartum (GD 104-114). This suggests that while not significantly different, the mean numbers of PEDV Ab + cells The highest mean numbers of PEDV IgA ASCs were in the ileum while the highest mean numbers of PEDV IgG ASCs were in spleen and ileum (Figures S8A,B) . Second trimester gilt mean numbers of IgA and IgG ASCs were significantly higher in the ileum than third and first trimester gilts, respectively. However, mock gilts had similar or higher mean numbers of IgA and IgG ASC in the spleen, mesenteric lymph node (MLN), and ileum compared with first, second, and third trimester gilts (Figures S8A,B) , corresponding to higher PEDV RNA shedding titers in feces and PEDV-induced diarrhea of mock gilts (Figures S6A,B) . Due to the high mortality rate of mock litters (Figure 7A ), the MGs of mock gilts regressed rapidly post piglet challenge (40) . There was not enough MG tissue left at PCD 21-29 to collect MG MNCs for ASC analysis.
DISCUSSION
Diarrheal disease represents a major global health burden and is the leading cause of morbidity and mortality in young children and animals. Specifically, the emergence of PEDV in the US in 2013 led to over 8.5 million piglet deaths and an estimated multimillion-dollar loss to the US swine industry (3, 41) . Maternal vaccination that enhances passively transferred protective Abs in milk, induced via the gut-MG-sIgA axis, is the major strategy to protect neonatal suckling piglets immediately after birth (4, 5). However, due to the biological and immunological differences at each stage of pregnancy (18) , the optimum time to induce maternal immunity and the gut-MG-sIgA axis was previously undefined. Here, we evaluated the impact of stage of gestation at PEDV infection on the maternal immune response, the generation of PEDV-specific ASCs and Abs in serum and milk . Asterisks indicate significant differences among treatment groups at the same time point (mean ± SEM). Statistical analysis was performed using the two-way ANOVA with repeated measures and Bonferroni's correction for multiple comparisons. *P < 0.05, **P < 0.01, ***P < 0.001.
and the protective effects of lactogenic immunity on PEDVchallenged piglets. A major finding of our study is that PEDV infection in the second trimester was the optimum stage of gestation to generate the highest maternal immune responses in blood and milk correlating to 100% lactogenic immune protection in PEDV challenged suckling piglets ( Table 1) . For example, second trimester gilts had the highest peak levels of circulating PEDV IgA and IgG ASCs and Abs and VN Abs prior to parturition. Interestingly, this coincided with higher serum cytokine concentrations of TGF-β (significantly) and IL-6 (numerically) at PID 0 in second trimester gilts. TGF-β a cytokine produced by multiple lineages of leukocytes and stromal cells (42) , is required for IgA class switch recombination (43) and IgA + B cell survival in the lamina propria (44) . Additionally, IL-6 promotes Ab production by increasing B cell helper capacity of CD4 + T cells (38) . Our data support previous research demonstrating increased serum TGF-β in women during the second trimester (45) correlating with increased Ab titers (46) . The increased serum TGF-β and IL-6 at PEDV infection in second trimester gilts likely contributed to the enhanced anti-PEDV maternal immune responses.
Despite being PEDV-infected 5 weeks earlier, first trimester gilts generated a lower maternal immune response during gestation compared with second trimester gilts ( Table 1) . This suggests stage of gestation dependent differences in immune parameters may contribute to differential induction of the humoral immune response during PEDV infection (47, 48) . The increase in NK cell frequencies at PID 0 in first compared with second and third trimester gilts (first trimester, GD 19-22; second trimester, GD 57-59; and third trimester, GD 96-97) is in agreement with previous studies reporting increased numbers of cytotoxic peripheral NK cells in first trimester women and swine (49) (50) (51) . Furthermore, the significantly higher circulating NK cell cytotoxicity at PID 6-8 coincided with enhanced mean concentrations of serum IL-12 and IL-22, NK cell activation, and proliferation cytokines, at PID 0 in first trimester gilts (29, (52) (53) (54) . Increased peripheral and decidual NK cell frequencies and lytic activity during the first trimester are thought to support maternal tissue remodeling during embryo implantation in swine and humans (20, 51, 55, 56) . Additionally, NK cells are known to modulate B cell immunity (57, 58) . Therefore, the unique immune environment during the first trimester may impact B cell responses to PEDV infection in pregnant gilts. Future studies investigating the effects of NK cells on the maternal immune response during an enteric viral infection in gilts are warranted.
We also hypothesized that stage of gestation would impact B cell phenotypes pre and post PEDV infection. For example, lymphocyte α4 + β7 + integrin is a mucosal adhesion molecule responsible for cellular migration in the intestinal mucosa and lymphoid tissue by interacting with its receptor mucosal addressin cellular adhesion molecule 1 (MAdCAM-1) (59-62). Circulating α4β7 + lymphocytes reflect the intestinal tissue in which they were primed (63) and may influence the gut-MG-sIgA axis. The significantly higher frequencies of α4 + β7 + B cells at PID 0 and 6-8 in second and third trimester, compared with first trimester gilts ( Table 1) , coincides with increased concentrations of immune modulating pregnancy-associated hormones in swine, like estrone, estrone sulfate, 17β-estradiol (E2), and E2 sulfate (64) . For example, trafficking of IgA + lymphoblasts to the MG in ovariectomized female mice was enhanced after E2 administration (65) . Additionally, E2 in combination with progesterone administration in ovariectomized female mice resulted in increased L-selectin and α4-dependent adhesion of NK cells to mucosal tissues (60) . Additionally, we observed differential effects of gestational stage on CD2 − CD21 + (primed and/or activated) B cell frequencies in blood. The significant increase in circulating CD2 − CD21 + B cell frequencies at PID 6-8 and 12-17 in second and third trimester compared with first trimester gilts is similar to the trend observed for α4β7 + B cell frequencies later in pregnancy ( Table 1) . The increasing concentrations of pregnancy-associated hormones as pregnancy progresses could modulate circulating frequencies of CD2 − CD21 + B cells, contributing to the differential immune responses observed in this study. Future studies treating ovariectomized swine with exogenous E2 or progesterone are needed to decipher the in vivo effects of pregnancy associated hormones on mucosal lymphocyte trafficking, B cell activation and ASC and Ab production.
To our knowledge, this is the first study to demonstrate an effect of stage of gestation at time of enteric viral infection on the gut-MG-sIgA axis and immune protection in suckling piglets. In our study, second trimester gilts provided greater passive lactogenic immune protection (100%) compared with first (87.2%) and third (55.9%) trimester and mock gilts (5.7%). The increased levels of protection were significantly correlated with PEDV IgA ASCs and Abs and VN Abs in colostrum and milk (Tables 1, 2) . These results are in agreement with previous work done with TGEV-infected pregnant swine. For example, high rates of protection against TGEV in piglets were achieved when pregnant sows were orally infected (6, 7, 13) with live virulent virus (14, 15) . The increased rate of protection was associated with high titers of IgA Abs in colostrum and milk induced via the gut-MG-sIgA axis (66) . Additionally, PEDV IgA and IgG Ab titers in piglet serum at PCD 0 correlated with piglet protection against PEDV challenge. In our study, we experimentally infected gilts with the same dose and strain of PEDV and controlled for parity and lack of prior TGEV-exposure. Therefore, we were able to observe correlates of immunity where second trimester gilts provided optimal protection in PEDV challenged suckling piglets correlating with levels of colostrum and milk PEDV IgA ASCs and Abs and VN Abs and piglet serum IgA and IgG Abs ( Table 1) . Experimental infection studies of gilts/sows with controlled PEDV doses and timing of piglet challenge post parturition are important for determining correlates of lactogenic immune protection against PEDV.
Lastly, we observed significantly higher PEDV RNA shedding titers at PID 2 and diarrhea scores at PID 4 in third trimester gilts. This suggests factors involved in intestinal homeostasis are impacted by the hormonal changes during the third trimester. For example, circulating E2 and porcine growth hormone concentrations increase in the third trimester prior to parturition (64) . There is growing evidence that hormones dynamically influence the gut microbiome (67) . Coincidently, the gut microbial environment during pregnancy changes dramatically from the first to third trimesters in humans (68, 69) and swine (70) resulting in decreased bacterial community richness. Additionally, studies of PEDV-infected pregnant sows revealed a significant decrease of observed bacterial species compared with healthy pregnant sows (71) . Although the gut microbiome was not examined in this study, it is possible that pregnancy hormone-induced effects on the gut microbiome during late pregnancy in combination with PEDV infection resulted in increased gut dysbiosis in third trimester pregnant gilts. Future studies investigating the impact of the microbiome during pregnancy on PEDV pathogenesis and the gut-MG-sIgA axis are warranted.
Previous research investigating stage of gestation at vaccination on the immune response in pregnant women reached conclusions similar to ours. Women vaccinated with the tetanus-diphtheria-acellular pertussis (Tdap) vaccine in the second and/or early third trimester had a higher concentration and avidity of anti-Tdap Abs in maternal blood and increased transplacental anti-Tdap Ab transfer compared with women immunized in the mid to late third trimester (72) (73) (74) . This is in agreement with our results, demonstrating that second trimester PEDV infection yields the highest titer of PEDV IgA, IgG, and VN Abs in serum and colostrum/milk. More research is needed in humans and livestock to better understand maternal immunity and to design the most effective maternal vaccines to passively protect suckling neonates and prevent neonatal morbidity and mortality.
In summary, a comparison of PEDV infection at different stages of gestation demonstrated that first, second and third trimester gilt immune responses vary greatly in magnitude of their immune response and association with lactogenic immune protection. We conclude that second trimester gilts have the greatest capacity to generate a robust anti-PEDV humoral immune response prior to parturition, resulting in the highest amount of lactogenic immune protection against PEDV challenge in neonatal suckling piglets. Additionally, piglet protection against PEDV challenge is correlated with PEDV IgA ASC, IgA Abs, and VN Abs in milk and PEDV IgA and IgG Abs in piglet serum (Tables 1, 2) . Our results provide novel insights and identify possible predictors of maternal vaccine efficacy for passive protection of suckling piglets. Finally, pregnancy should not be evaluated as a single event and development of a successful attenuated PEDV vaccine requires consideration of stage of gestation at the time of vaccination.
MATERIALS AND METHODS
Virus
The wild-type PC22A strain of PEDV was used for gilt infection and piglet challenge at a dose of 1 × 10 5 plaque forming units (PFU) diluted in Minimal Essential Media [MEM (Life Technologies, Carlsbad, CA)]. Briefly, PC22A was isolated and cultured in Vero cells as described previously (75, 76) . Cells were grown in growth medium containing Dulbecco's Modified Eagle's Medium [DMEM (Life Technologies, Carlsbad, CA)] supplemented with 5% fetal bovine serum (Life Technologies, Carlsbad, CA) and 1% antibiotic-antimycotic (Life Technologies, Carlsbad, CA). Virus was grown in Vero cells in maintenance medium containing DMEM supplemented with 10 µg/ml trypsin (Life Technologies, Carlsbad, CA), 0.3% tryptose phosphate broth (Sigma Aldrich, St. Louis, MO), and 1% antibioticantimycotic. Cells were kept in a humidified incubator at 37 • C and 5% CO 2 . PC22A was passaged three times in Vero cells before passaging once for generation of inoculum in a gnotobiotic pig. The virulence of pig passaged PC22A was confirmed in adult and neonatal pigs (4, 77, 78) . Cell-culture adapted PC22A was used as a positive control in the VN Ab assay.
Experimental Design
All animal experiments were approved by the Institutional Animal Care and Use Committee at The Ohio State University. All pigs were maintained, sampled, and euthanized humanely. First parity PEDV, porcine deltacoronavirus (PDCoV) and TGEV seronegative pregnant gilts (Landrace × Yorkshire × Duroc cross-bred) were acquired from either Wilson Farms (Elkhorn, WI) or The Ohio State University swine center facility and randomly assigned to one of four treatment groups: PEDVinfected (1) first trimester (GD 19-22) (n = 10); (2) second trimester (GD 57-59) (n = 7); or (3) third trimester (GD 96-97) (n = 6) or MEM-infected third trimester control [GD 96-97 (n = 4)] (Figure 1A) . Second and third trimester gilts arrived at our facilities at GD 49-51 and 89-92, respectively, and acclimated for 1 week prior to PEDV infection. First trimester gilts were housed and PEDV-infected at the National Animal Disease Center, USDA-ARS, in Ames, Iowa and then four gilts were shipped to our facilities at GD 93 after they were determined to be fecal shedding negative by real-time quantitative polymerase chain reaction (RT-qPCR). Gilt fecal samples were collected, and clinical signs observed on PID 0, 2, 4, 6, 10, and 14. Fecal consistency was scored as follows: 0, solid; 1, pasty; 2, semiliquid; 3, liquid, respectively. A fecal consistency score of >1 was considered as diarrhea (4, 77) . Blood samples were collected post-PEDV infection at PID 0, 6-8 and 12-17 and also prior to parturition at GD 82-95, 98-102, and 104-114 for serum and mononuclear cell (MNC) isolation. All gilts farrowed naturally in our facilities at GD 114 (± 3) and colostrum was collected within 12 h of parturition. Piglets were orally PEDV-challenged at 3-5 days of age (mean ± SD challenge day for first trimester litters = 4.0 ± 0.82, second trimester litters = 4.4 ± 0.96, third trimester litters = 4.2 ± 0.82 and mock litters = 3.7 ± 0.96). Gilt and piglet serum were collected on PCD 0, 5-9, 12-17, and 21-29. All colostrum and milk samples were collected after administration of 2cc oxytocin intramuscularly (IM) at PPD 0, 3-5, 8-14 , and 15-22 ( Figure 1B) . Gilt MG biopsies were collected at GD 104-114 and PPD 8-14. Piglet fecal samples were collected and clinical signs and body weights were recorded daily on PCD 0-7 and every other day through PCD 15-17. All animals were euthanized at PCD 21-29. Upon euthanasia, gilt blood, ileum, MG, MLN, and spleen tissues were collected for MNC isolation. Piglet blood was collected and the serum separated for immunologic assays.
PEDV RNA Quantification by RT-qPCR
To determine PEDV RNA shedding titers, two rectal swabs were suspended in 4 mL MEM as described previously (78) . Viral RNA was extracted from 50 µl of fecal supernatants following centrifugation (2,000 × g for 30 min at 4 • C) using the MagMAX Viral RNA Isolation Kit (Applied Biosystems, Foster City, CA) according to the manufacturer's instructions. Titers of viral RNA shed in feces were determined by TaqMan RTqPCR using the Onestep RT-PCR Kit (QIAGEN, Valencia, CA) (78). The detection limit was 10 copies per 20 µL of reaction, corresponding to 4.8 log 10 copies/mL of original fecal samples.
Isolation of MNCs in Blood, Spleen, MLN, and Ileum
Blood, spleen, MLN, and ileum were collected aseptically at euthanasia and processed for MNC isolation as described previously (79) . The isolated cells were resuspended in enriched RPMI [E-RPMI (Roswell Park Memorial Institute)] medium containing 8% fetal bovine serum, 2 mM l-glutamine, 1 mM sodium pyruvate, 0.1 mM non-essential amino acids, 20 mM HEPES (N-2-hydroxy-ethylpiperazine-N−2-ethanesulfonic acid), and 1% antibiotic-antimycotic (Life Technologies, Carlsbad, CA) and used for assays. The viability of MNCs was determined by trypan blue exclusion. Briefly, MNCs were diluted two-fold in 0.4% trypan blue before visualizing using an automated cell counter (Cellometer, Nexcelom, Lawrence, MA). The viability (%) was calculated as [1.00-(number of blue cells/numbers of total cells)] × 100.
Isolation of MNCs From the MG Tissue
The MG was collected aseptically at euthanasia and placed in ice-cold wash medium (RPMI 1640 with 
Detection of Cytokines in Serum by ELISA
Serum samples were processed and analyzed for proinflammatory (TNF-α, IL-6, IL-17, IL-22), innate (IFN-α) and Th1 (IL-12, IFN-γ), Th2 (IL-4), and T regulatory (IL-10 and TGF-β) cytokines as described previously with some modifications (80, 81) . Briefly, Nunc Maxisorp 96-well plates were coated with anti-porcine IL-4 (2 µg/ml, clone A155B16F2), anti-porcine IL-10 (4 µg/ml, clone 945A4C437B1), anti-porcine IFN-γ (1.5 µg/ml, clone A151D5B8), anti-porcine TGF-β (1.5 µg/ml, clone 55B16F2) (Thermo Fisher Scientific, Waltham, MA), anti-porcine IL-6 (0.75 µg/ml, goat polyclonal Ab), antiporcine IL-12 (0.75 µg/ml, goat polyclonal Ab), anti-porcine IFN-α (2.5 µg/ml, clone K9) (R&D systems, Minneapolis, MN), anti-porcine TNF-α (1.5 µg/ml, goat polyclonal Ab), anti-porcine IL-17 (1.5 µg/ml, rabbit polyclonal Ab), and anti-porcine IL-22 (1.5 µg/ml, rabbit polyclonal Ab) (Kingfisher Biotech, Saint Paul, MN) overnight at 37 • C for IFN-α or 4 • C for all other cytokines. Biotinylated anti-porcine IL-4 (0.5 µg/ml, clone A155B15C6), anti-porcine IL-10 (1 µg/ml, clone 945A1A926C2), anti-porcine IFN-γ (0.5 µg/ml, clone A151D13C5), anti-TGF-β (0.4 µg/ml, TGF-β-1 Multispecies Ab Pair CHC1683) (Thermo Fisher Scientific, Waltham, MA), anti-porcine IL-6 (0.1 µg/ml, goat polyclonal IgG), anti-porcine IL-12 (0.2 µg/ml, goat polyclonal IgG), anti-porcine IFN-α (3.75 µg/ml, clone F17) (R&D systems, Minneapolis, MN), anti-porcine TNF-α (0.4 µg/ml, goat polyclonal Ab), anti-porcine IL-17 (1 µg/ml, rabbit polyclonal Ab) or anti-porcine IL-22 (1 µg/ml, rabbit polyclonal Ab) (Kingfisher Biotech, Saint Paul, MN) were used for detection. Porcine IFN-α detection Ab was biotinylated using a commercial kit as described previously (81) . Plates were developed and cytokine concentrations were calculated as described previously (80) . Sensitivities for these cytokine ELISA assays were 1 pg/ml for IL-4, IL-12, and IFN-α, 4 pg/ml for TNF-α, IL-17, and IL-22, 8 pg/ml for TGF-β, and 16 pg/ml for IL-6, IL-10, and IFN-γ.
Colostrum/Milk Processing for Whey and Isolation of MNCs
Colostrum/milk was collected aseptically after gilts were given 2cc oxytocin (VetOne, Boise, ID) IM to facilitate collection of mammary secretions. Colostrum/milk was placed immediately on ice. Samples were filtered through a 70 µM pore filter and centrifuged at 1,800 × g for 30 min at 4 • C to separate fat, skim milk, and cell pellet portions. Fat was removed utilizing sterile plain-tipped applicators (Fisher Scientific, Hampton, NH). Skim milk was collected, centrifuged at 28,000 × g for 1 h at 4 • C to separate the whey that was then stored at −20 • C until tested. The cell pellet portion was resuspended in a 90% Percoll solution and centrifuged at 1,200 × g for 30 min at 4 • C. Cell pellets were resuspended in 43% Percoll, underlaid with 70% Percoll, and centrifuged at 1,200 × g for 30 min at 4 • C. The MNC were collected from the 43-to-70% interface and washed with wash medium. Cells were filtered through a 70 µM pore filter and resuspended in E-RPMI. The viability of the MNC preparation was determined by trypan blue exclusion.
NK Cell Cytotoxicity Assay
Blood MNC and K562 cells were used as effector and target cells, respectively. Effector: target cell ratios of 10:1, 5:1, and 1:1 were used and the assay was done as described previously (82) .
Flow Cytometry to Assess NK Cell Frequencies
To determine the frequencies of NK cells, CD3 − , CD172 − , CD8 + MNCs were identified. Briefly, 100 µl of peripheral blood mononuclear cells (PBMCs) at 1 × 10 7 cells/ml were stained with anti-porcine CD3 (clone PPT3, Southern Biotech), anti-porcine SWC3a [CD172 human analog (clone 74-22-15, Southern Biotech)] and anti-porcine CD8 (clone 76-2-11, Southern Biotech) monoclonal Abs (mAbs) for 15 min at 4 • C. Subsequently cells were washed and incubated with streptavidin APC (BD Biosciences, San Jose, CA, USA) secondary Ab. Appropriate isotype matched control Abs were included. Acquisition of 50,000 events and analyses were done using the Accuri C6 flow cytometer (BD Biosciences). The gating strategy is depicted in Figure S1 .
PEDV Plaque Reduction VN Assay
A plaque reduction VN assay was performed as described previously (83) with modifications. Serum and whey were inactivated at 56 • C for 30 min prior to testing for PEDV neutralizing Abs. Serial 4-fold dilutions of test sera or whey were mixed with 70 PFU and 140 PFU PEDV PC22A cell-culture adapted strain, respectively. The serum/whey-virus mixtures (290 µl/well) were incubated for 1.5 h at 37 • C with gentle rocking and then duplicate samples were infected onto 2-3 day confluent Vero cell monolayers in 6-well plates. Plates were incubated at 56 • C for 1 h, lightly rocking every 15 min. Subsequently, the inoculum was removed, cells were washed twice with sterile PBS [1X pH 7.4 (Sigma Aldrich, St. Louis, MO)] and overlaid with 0.75% low melting point agarose (SeaPlaque, Lonza, Riverside, PA) in serum free media supplemented with tryptose phosphate broth and trypsin as described for PEDV cultivation (75) . Plates were incubated at 37 • C for 3 days and then stained with 0.001% neutral red solution (Sigma Aldrich, St. Louis, MO). Plaques were counted and the VN titers were determined by calculating the reciprocal of the highest dilution of a serum/whey sample showing an 80% reduction in the number of plaques compared with seronegative control serum/whey.
PEDV Whole Virus Ab ELISA
Cell culture adapted PC22A was propagated on 2-3-day-old Vero cells in polystyrene roller bottles (Fischer Scientific, Hampton, NH) until the cells demonstrated 90-95% cytopathic effects (CPE). Roller bottles were subjected to two freeze-thaw cycles at −80 • C before collecting the supernatant and centrifuging at 3,000× g for 10 min at 4 • C to remove Vero cell debris. The supernatant was overlayed onto 3 ml sucrose [35% in TNC buffer (50 mM Tris at pH 7.4, 150 mM NaCl, 10 mM CaCl 2 , 0.02% NaN 3 )] and centrifuged at 112,700 × g for 2 h at 4 • C. The viral pellet was resuspended in TNC buffer, centrifuged at 107,200 × g for 2 h at 4 • C and washed twice with sterile PBS (1X pH 7.4). Then the viral pellet was inactivated by using binary ethylenimine (BEI) as previously described (84) Plates were incubated at RT for 5 min and stopped by addition of 100 µl stop solution (1 M sulfuric acid) to each well. Reactions were measured as optical density at 450 nm using an ELISA plate reader (Spectramax 340pc, Molecular Devices, San Jose, CA). The ELISA Ab titer was expressed as the reciprocal of the highest dilution that had a corrected A 450 value (sample absorbance in the virus-coated well minus sample absorbance in the mock antigen-coated well) greater than the cut-off value (mean corrected A 450 value of negative controls plus 3 standard deviations). Samples negative at a dilution of 1:4 were assigned a titer of 1:2 for the calculation of geometric mean titers (GMTs).
PEDV Antibody Secreting Cell ELISPOT
To detect PEDV ASCs, PEDV PC22A, and mock-infected, acetone-fixed Vero cells in 96-well plates were used similar to methods used to detect TGEV ASC (85, 86 were obtained using a fluorescence microscope (Olympus IX70-S1F2). Mean numbers of PEDV Ab + cells were evaluated by measuring at least 3 different microscopic fields at (30× magnification) for each sample time point (GD 104-114 and PCD 5-9) from first, second and third PEDV-infected or mock gilts.
Flow Cytometry to Assess Lymphocytes and Homing Marker Integrin and Receptor Frequencies
Procedures for flow cytometry staining (including buffers used) were performed as described previously with minor modifications (87) . Briefly, 100 µl of MNCs at 1 × 10 7 cells/ml were stained with anti-porcine CD21-PE (clone BB6-11C9.6, Southern Biotech) and anti-porcine CD2 (clone MSA4, VMRD) monoclonal Abs (mAbs) to determine B cell subsets (88) . To determine expression of α4 integrin, β7 integrin and CCR10, cells were stained with porcine cross-reactive anti-human α4 integrin (clone HP2/1, Abcam, Cambridge, MA), anti-mouse β7 integrin (clone FIB27, BD Biosciences), and anti-mouse CCR10 (clone 248918, R&D Systems) mAbs. Additionally, to determine expression of IgA, cells were stained with anti-porcine IgA (clone K61 1B4, Bio-Rad) mAb. 
